MAPT and early-onset autosomal dominant Alzheimer disease: To date, the most promising [18F]-labeled tau ligands are the pyrdioleindole [18F]-AV1451 (T807) and the arylquinoline [18F]-THK5351 (Harada et al., 2016), both of which have already been investigated in Alzheimer's disease.